Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?

GRACE Videos and Articles

LCAM 2015

 

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

[powerpress]

Get more information about the ALEX Trial.

[ratingwidget post_id=0]

Check out more LCAM videos & posts here.

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation